AR024109A1 - Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa - Google Patents

Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa

Info

Publication number
AR024109A1
AR024109A1 ARP000102572A ARP000102572A AR024109A1 AR 024109 A1 AR024109 A1 AR 024109A1 AR P000102572 A ARP000102572 A AR P000102572A AR P000102572 A ARP000102572 A AR P000102572A AR 024109 A1 AR024109 A1 AR 024109A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
formula
cyano
independently
Prior art date
Application number
ARP000102572A
Other languages
English (en)
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of AR024109A1 publication Critical patent/AR024109A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/51Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04Derivatives of thiourea
    • C07C335/16Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04Derivatives of thiourea
    • C07C335/16Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/18Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30Isothioureas
    • C07C335/32Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/36One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4021Esters of aromatic acids (P-C aromatic linkage)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos de formula (1), en donde R1 y R2 son sustituyentes de los anillos A y son, independientemente, -SO2NR72, -C(O)NR72, -NR7SO2R7, -NR7C(O)R7,-SO2OR7, -C(O)OR7, -OSO2R7, o -OC(O)R7; R3 y R4 son, independientemente, hidrogeno o alquilo inferior, o R3 y R4 conjuntamente son -(CH2)2-, -(CH2)3-, o-(CH2)4-, o R3 o R4 pueden ser un par electronico; R5 y R6 son, independientemente, hidrogeno, alquilo, alquilo sustituido, ciano, halo, nitro, -SR8, -C(O)R8,-SO2OR8, -OSO2R8, -SO2NR82, -NR8SO2R8, -OC(O)R8, -C(O)OR8, -C(O)NR82,NR8C(O)R8, -OR8, o -NR82; cada uno de R7 y R8 es, independientemente, hidrogeno, alquilo,alquilo sustituido, arilo, arilo sustituido, arilalquilo (inferior), arilalquilo (inferior) sustituido, heteroarilalquilo(inferior),heteroarilalquilo(inferior)sustituido, heterociclilo, heterociclilo sustituido, heteroarilo, o heteroarilo sustituido; cada Y es, independientemente, un sustituyente no interferente queno está unido al anillo de naftaleno por medio de un enlace azo oamida; cada x es, independientemente, 0, 1, o 2, y el nexo es un compuesto de formula (2)donde K es O, S, o N-R*, y R* es H, ciano o alquilo inferior; o un compuesto de formula (3) o (4) donde R* es H o alquilo inferior; o un compuesto de formula(5)o (6) donde R* es H, ciano o alquilo inferior; o un compuesto de formula (7) donde R* es ciano o alquilo inferior; y donde, si R1 y R2 son ambos -SO2OH,entonces: (i) ningun grupo Y es -SO2OH; (ii) ni R5 ni R6 son -SO2OR8 u -OSO2R8; y (iii) R5 y R6 nose eligen ambos del grupo integrado por hidroxi e hidrogenoa no ser que al menos un grupo (Y)x sea (Y)x, en donde x es 1 o 2 e Y es un halogeno, o una sal farmacéuticamente aceptable del mismo, como estereoisomerounico o como mezcla de estereoisomeros, son utiles para tratar condiciones asociadas a la hiperglucemia, especialmente la diabetes de tipo II, condinaftilureas. Estos compuestos son utiles en la estimulacion de la actividad de quinasa del receptor insulínico, la activacion del receptorinsulínico, y laestimulacion de la captacion de glucosa. También se describen composiciones farmacéuticas que comprenden los compuestos antidiabéticos.
ARP000102572A 1999-05-26 2000-05-26 Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa AR024109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13612899P 1999-05-26 1999-05-26

Publications (1)

Publication Number Publication Date
AR024109A1 true AR024109A1 (es) 2002-09-04

Family

ID=22471427

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102572A AR024109A1 (es) 1999-05-26 2000-05-26 Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa

Country Status (26)

Country Link
US (2) US6458998B1 (es)
EP (1) EP1181271B1 (es)
JP (1) JP2003500381A (es)
KR (1) KR100746870B1 (es)
CN (1) CN1364156A (es)
AR (1) AR024109A1 (es)
AT (1) ATE287394T1 (es)
AU (1) AU776438C (es)
BR (1) BR0011550A (es)
CA (1) CA2374225A1 (es)
CZ (1) CZ20014153A3 (es)
DE (1) DE60017554T2 (es)
EA (1) EA006763B1 (es)
ES (1) ES2233386T3 (es)
HK (1) HK1046399A1 (es)
HU (1) HUP0201306A3 (es)
IL (2) IL146576A0 (es)
MX (1) MXPA01012079A (es)
NO (1) NO20015713L (es)
NZ (1) NZ515743A (es)
PL (1) PL352631A1 (es)
TR (1) TR200103409T2 (es)
TW (1) TWI234557B (es)
UA (1) UA73738C2 (es)
WO (1) WO2000071506A2 (es)
ZA (1) ZA200109641B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7058589B1 (en) * 1998-12-17 2006-06-06 Iex Corporation Method and system for employee work scheduling
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
ITTO20010950A1 (it) * 2000-10-11 2003-04-09 Telik Inc Attivatori di recettori di insulina per il trattamento di disturbi metabolici in esseri umani che risultano dal trattamento di infezioni da
US6528037B2 (en) 2000-10-11 2003-03-04 Telik, Inc. Method for determining whether a compound is an insulin receptor kinase activator
PE20021091A1 (es) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
JP4636486B2 (ja) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
DE60327543D1 (de) 2002-10-21 2009-06-18 Janssen Pharmaceutica Nv Substituierte tetraline und indane und ihre verwendung
DK1636585T3 (da) 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
BRPI0412219B8 (pt) 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
NZ563131A (en) 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
AU2012200933B2 (en) * 2005-06-22 2015-04-30 Plexxikon, Inc. Pyrrolo [2, 3-B] pyridine derivatives as protein kinase inhibitors
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
NZ567132A (en) * 2005-09-09 2011-12-22 Vertex Pharma Bicyclic derivatives as modulators of voltage gated ion channels
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
NZ594398A (en) 2009-04-03 2014-03-28 Plexxikon Inc Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
KR20120102669A (ko) 2009-11-06 2012-09-18 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 방법, 및 이를 위한 적응증
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH488212A (de) * 1967-09-01 1970-03-31 Ciba Geigy Photographisches Material
US4118232A (en) * 1971-04-07 1978-10-03 Ciba-Geigy Ag Photographic material containing sulphonic acid group containing disazo dyestuffs
CA985675A (en) * 1971-04-07 1976-03-16 Ciba-Geigy Ag Azo dyestuffs, their manufacture and use
US4051176A (en) * 1976-05-10 1977-09-27 American Cyanamid Company Ureidophenylenebis(carbonylimino)dinaphthalenetrisulfonic acid compounds
US4129591A (en) * 1976-10-27 1978-12-12 American Cyanamid Company Ureida-phenylenebis(substituted imino)multianionic substituted dinaphthalene sulfonic acids and salts
US4102917A (en) * 1977-06-01 1978-07-25 American Cyanamid Company Substituted phenyl naphthalenesulfonic acids
US4120891A (en) * 1977-07-01 1978-10-17 American Cyanamid Company Ureylene naphthalene sulfonic acids
US4132730A (en) * 1977-07-29 1979-01-02 American Cyanamid Company Ureylene naphthalene sulfonic acids
JPS58191772A (ja) * 1982-05-06 1983-11-09 Canon Inc 記録液及びこれを用いたインクジェット記録方法
US4591604A (en) * 1984-03-28 1986-05-27 American Cyanamid Company Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
DE19521589A1 (de) * 1995-06-14 1996-12-19 Bayer Ag Polyfunktionelle Azoreaktivfarbstoffe
DK0960335T3 (da) * 1997-01-15 2005-06-20 Telik Inc Modulatorer af insulinreceptoraktivitet
US5830918A (en) * 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
US6140368A (en) * 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods

Also Published As

Publication number Publication date
CA2374225A1 (en) 2000-11-30
WO2000071506A3 (en) 2001-08-09
AU776438B2 (en) 2004-09-09
EA006763B1 (ru) 2006-04-28
HUP0201306A3 (en) 2005-04-28
NZ515743A (en) 2003-08-29
AU5168400A (en) 2000-12-12
US6458998B1 (en) 2002-10-01
ES2233386T3 (es) 2005-06-16
AU776438C (en) 2005-07-28
HUP0201306A2 (en) 2002-09-28
TWI234557B (en) 2005-06-21
US7071231B2 (en) 2006-07-04
BR0011550A (pt) 2002-06-04
IL146576A0 (en) 2002-07-25
JP2003500381A (ja) 2003-01-07
KR20020022679A (ko) 2002-03-27
TR200103409T2 (tr) 2002-05-21
IL146576A (en) 2006-10-05
CN1364156A (zh) 2002-08-14
KR100746870B1 (ko) 2007-08-07
EP1181271B1 (en) 2005-01-19
UA73738C2 (en) 2005-09-15
US20030135063A1 (en) 2003-07-17
EP1181271A2 (en) 2002-02-27
HK1046399A1 (en) 2003-01-10
DE60017554T2 (de) 2006-03-30
ATE287394T1 (de) 2005-02-15
NO20015713L (no) 2001-12-20
DE60017554D1 (de) 2005-02-24
PL352631A1 (en) 2003-08-25
ZA200109641B (en) 2003-02-24
EA200101231A1 (ru) 2002-06-27
MXPA01012079A (es) 2003-06-30
NO20015713D0 (no) 2001-11-23
WO2000071506A9 (en) 2001-09-20
WO2000071506A2 (en) 2000-11-30
CZ20014153A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
AR024109A1 (es) Naftalen ureas novedosas como mejoradoras de la captacion de la glucosa
AU616185B2 (en) Oxazolidinones
AR056893A1 (es) Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR061644A1 (es) Derivados de benzofurano
PE20061377A1 (es) Compuestos heterociclicos fusionados
PE20010645A1 (es) Compuestos espiro como antagonistas de los receptores del neuropeptido y
PE20020061A1 (es) Fenil sulfamoil carboxamidas sustituidas
AR034985A1 (es) Compuesto biciclico; produccion y uso del mismo
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
PE20030385A1 (es) Compuestos de urea como antagonistas de receptores y5 del neuropeptido y
CO5040071A1 (es) Derivados de aminas biciclicas, procesos para su prepara- cion, y composiciones insecticidas que los comprenden
AR057771A1 (es) Agonistas adrenoreceptores alfa2c
NO20091678L (no) Modulatorer av glucokortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og deres anvendelse
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
AR087494A1 (es) Derivados de isoxazolina como compuestos insecticidas
PE20081164A1 (es) Nuevos compuestos 521
NZ527249A (en) Purine derivatives as purinergic receptor antagonists
CO6230982A2 (es) Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
ATE433440T1 (de) Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure